Aim

To help guide antibiotic selection in children with allergies, a risk stratification approach has been adopted based on the current available evidence.

Background

Beta-lactams are the most commonly used antibiotics and include penicillins (e.g. amoxicillin, piperacillin, benzylpenicillin), cephalosporins (e.g. cefalexin, ceftriaxone) and carbapenems (e.g. meropenem). Similarly Beta-lactam allergies are the most frequently reported antibiotic reactions in children.

Recent data support that the majority of patients who are ‘labelled’ with a Beta-lactam allergy can in fact tolerate the antibiotic in question without the need for skin testing.\(^1\)\(^,\)\(^2\)

Moreover, the use of alternative antibiotics for patients labelled with allergy leads to poorer clinical outcomes, prolonged hospitalisation, increased costs and increased adverse effects.\(^3\)\(^-\)\(^6\)

The risk stratification system used in this guideline is a safe but simplified approach to a very complex issue. An individualised approach may be required in certain settings.

Risk Classification

Beta-lactam allergies can be classified into high risk and low risk based on the likelihood of subsequent reaction upon exposure.\(^7\)\(^,\)\(^8\)

- **No risk:** no previous reaction; non-immune mediated intolerances (e.g. nausea, diarrhoea); family history of Beta-lactam allergy.

- **Low risk:** a delayed rash (>1hr after initial exposure) without mucosal or systemic involvement (without respiratory distress and/or cardiovascular compromise).

- **High risk:** an immediate rash (<1hr after exposure); anaphylaxis; severe cutaneous adverse reaction (e.g. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) and Stevens – Johnson syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)) or other severe systemic reaction.
Management
The Children’s Antimicrobial Management Programme (ChAMP) guidelines stratify recommendations based on Beta-lactam allergy and risk classification.

Low risk: alternate antibiotic as per ChAMP* AND
  - >1yr since reaction: consider oral challenge for PCH inpatients if stable#
  - <1yr since reaction: immunology outpatient referral to explore allergy / de-labelling

- High risk: immunology referral, alternate antibiotic as per ChAMP**

*Refer to individual guidelines for specific antibiotic recommendations
#Immunology inpatient consult required for all oral challenges

The majority of true Beta-lactam allergies are mediated by reactivity to the side chains present on the beta-lactam ring. Antibiotics with similar side chains in both the penicillin and cephalosporin classes carry a higher risk of cross reaction (Figure 1). There is a very low risk of cross reaction (<2%) if a beta-lactam with a different side chain is administered.

**For high risk patients a non-Beta-lactam antibiotic is recommended. Refer to individual guidelines for specific antibiotic recommendations. In selected patients with a history of high-risk allergy, a Beta-lactam from another subclass (e.g. a cephalosporin or carbapenem) may be considered in discussion with immunology.

Oral Challenge
At present inpatient oral challenges are reserved for low-risk patients admitted to PCH in discussion with immunology – for other patients labelled with Beta-lactam allergy complete an outpatient referral to PCH immunology.

Please refer to: Antibiotic Challenge (Immunology) Protocol
Figure 1: Antibiotics grouped by similar side chain. 

Legend:
- In vitro data proposed cross-reactivity between cefoxitin and cephalothin based upon shared but not shared R1.
- Exactly the same drug.
- R1 - Identical R1 side chain.
- R1* - Almost Identical R1 side chain.
- R2 - Identical R2 and non-identical R1 with some cross-reactivity.
- R1° - Non-identical R1 with some clinical cross-reactivity.
- Shared class specific ring but no shared side chain structure.
- No shared class specific ring, only shared beta-lactam ring.
- No shared cross reactivity with beta-lactam ring.
Related internal policies, procedures and guidelines

**Allergic Reactions and Anaphylaxis – Management for Planned Allergy Challenges (Immunology)**

**Antibiotic Challenge**

---

**References**


This document can be made available in alternative formats on request for a person with a disability.

<table>
<thead>
<tr>
<th>File Path:</th>
<th>W:\Safety &amp; Quality\CAHS\CLOVERS MEDICAL Pharmacy\Procedures Protocols and Guidelines\ChAMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Owner:</td>
<td>Infectious Diseases Head of Department</td>
</tr>
<tr>
<td>Reviewer / Team:</td>
<td>Children’s Antimicrobial Management Program</td>
</tr>
<tr>
<td>Date First Issued:</td>
<td>March 2020</td>
</tr>
<tr>
<td>Last Reviewed:</td>
<td>New</td>
</tr>
<tr>
<td>Review Date:</td>
<td>March 2023</td>
</tr>
<tr>
<td>Approved by:</td>
<td>Medication Safety Committee</td>
</tr>
<tr>
<td>Date:</td>
<td>March 2020</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Drug and Therapeutics Committee</td>
</tr>
<tr>
<td>Date:</td>
<td>March 2020</td>
</tr>
<tr>
<td>Standards Applicable:</td>
<td>NSQHS Standards: 🌺 🌺 🌺</td>
</tr>
</tbody>
</table>

Printed or personally saved electronic copies of this document are considered uncontrolled.